ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0274

Cost and Healthcare Resource Use in Patients with Anemia in CKD Using Linked US Claims and Electronic Health Records

Session Information

Category: Anemia and Iron Metabolism

  • No subcategory defined

Authors

  • Wittbrodt, Eric T., AstraZeneca, Wilmington, Delaware, United States
  • James, Glen, AstraZeneca, Cambridge, United Kingdom
  • Kumar, Supriya R., AstraZeneca, Gaithersburg, Maryland, United States
  • Garcia Sanchez, Juan Jose, AstraZeneca, Cambridge, United Kingdom
  • Chen, Hungta (tony), AstraZeneca, Gaithersburg, Maryland, United States
  • Kalantar-Zadeh, Kamyar, University of California - Irvine, Irvine, California, United States
  • Sloand, James A., AstraZeneca, Gaithersburg, Maryland, United States
Background

Anemia is a routinely occurring complication in patients with chronic kidney disease (CKD), but current data regarding its economic impact are lacking. This study described direct costs and healthcare resource utilization in non-dialysis CKD patients with and without baseline anemia in real-world practice.

Methods

This retrospective analysis of the integrated Limited Claims and Electronic Health Record (IBM Health, Armonk, NY) spanned Jan 1, 2012 to Sept 30, 2018. Patients were aged ≥18 years with ≥2 eGFR measures <60 mL/min/1.73 m2 ≥90 days apart. Anemia was defined as any hemoglobin (Hb) value <10 g/dL observed within 6 months of confirmatory eGFR (baseline period). Total and site-specific costs and selected healthcare resource utilization were analyzed and stratified by presence of baseline anemia, Hb range, CKD stage, sex, and insurance type.

Results

Of 22,720 patients, 23% (n=5283) had baseline anemia, 77% (17,437) did not; females accounted for 60% and 56% of the patients, mean ages (± SD) were 70 (14) and 70 (12) years, and median follow-up times were 2.9 and 3.8 years, respectively. Baseline anemia prevalence by CKD stage was 18% (stage 3a), 25% (3b), 41% (4), and 73% (5). Median per patient total costs were $49012 and $31667, total hospitalization costs were $33479 and $22695, and total ER costs were $2232 and $1891, respectively. Median annual number of transfusions doubled (2 vs 1) and annual transfusion cost was 50% greater in patients with vs without baseline anemia, respectively. Slightly increased costs were associated with male sex and were markedly increased by advancing CKD stage (>3a), baseline Hb <10, and supplemental Medicare and non-capitated insurance coverage.

Conclusion

Anemia is associated with substantially added direct cost and healthcare resource utilization experienced by patients with non-dialysis CKD, in both early and advanced stages and with lower Hb. Effective management of anemia in CKD offers an opportunity to address this ongoing burden.

Funding

  • Commercial Support